HOME >> BIOLOGY >> NEWS
Neanderthal genome sequencing yields surprising results and opens a new door to future studies

The veil of mystery surrounding our extinct hominid cousins, the Neanderthals, has been at least partially lifted to reveal surprising results. Scientists with the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and the Joint Genome Institute (JGI) have sequenced genomic DNA from fossilized Neanderthal bones. Their results show that the genomes of modern humans and Neanderthals are at least 99.5-percent identical, but despite this genetic similarity, and that the two species cohabitated the same geographic region for thousands of years, there is no evidence of any significant crossbreeding between the two. Based on these early results, Homo sapiens and Homo neanderthalensis last shared a common ancestor approximately 700,000 years ago

In a paper published in the November 17, 2006 issue of the journal Science, a team of researchers led by Edward Rubin, director of both JGI and Berkeley Lab's Genomics Division, reports the development of a "Neanderthal metagenomic library," which they used to characterize more than 65,000 DNA base pairs of Neanderthal origin. Their results not only provide new information about Neanderthals, but also point the way to a new strategy for studying aspects of Neanderthal biology that would never be evident from archaeological artifacts and fossils.

In addition, the technology described in the paper also marks an important advance in the field of metagenomics, which is increasingly being used to sequence the complex mixtures of microbes found in the environment. Metagenomics techniques are considered crucial for tapping the potential of Earth's more exotic microbe-containing environments to find bio-based solutions to problems of renewable energy production, environmental clean-up, and carbon sequestration, as well as breakthroughs in critical areas such as pharmaceuticals and agriculture.

"The current state of our knowledge concerning Neanderthals and their relationship
'"/>

Contact: Lynn Yarris
lcyarris@lbl.gov
510-486-5375
DOE/Lawrence Berkeley National Laboratory
15-Nov-2006


Page: 1 2 3 4 5

Related biology news :

1. Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals
2. Neanderthal reconstructed
3. Unravelling new complexity in the genome
4. One species, many genomes
5. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
6. Charting ever-changing genomes
7. Neutral evolution has helped shape our genome
8. Sea anemone genome provides new view of our multi-celled ancestors
9. Cloning the male genome may help infertile men
10. Mutating the entire genome
11. Exploring the dark matter of the genome

Post Your Comments:
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: